Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence

Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol Cancer Therapeutics, 2, 471

Kim, 2006, An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases, J Clin Endocrinol Metab, 91, 4070, 10.1210/jc.2005-2845

Mendel, 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin Cancer Res, 9, 327

Murray, 2003, SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model, Clin Exp Metastasis, 20, 757, 10.1023/B:CLIN.0000006873.65590.68

O’Farrell, 2003, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101, 3597, 10.1182/blood-2002-07-2307

Ljungberg B, Hanbury D, Kuczyk M. Guidelines on renal cell carcinoma. Arnhem, the Netherlands: European Association of Urology; 2007. http://www.uroweb.org/fileadmin/tx_eauguidelines/Renal%20Cell%20Carcinoma.pdf.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer V.1.2008. Fort Washington, PA: NCCN; 2008. http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf.

Gnarra, 1994, Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat Genet, 7, 85, 10.1038/ng0594-85

Iliopoulos, 1996, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein, Proc Natl Acad Sci U S A, 93, 10595, 10.1073/pnas.93.20.10595

Kondo, 2002, Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters, Genes Chromosomes Cancer, 34, 58, 10.1002/gcc.10054

Na, 2003, Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas, J Urol, 170, 588, 10.1097/01.ju.0000074870.54671.98

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516

Motzer, 2007, Sunitinib efficacy against advanced renal cell carcinoma, J Urol, 178, 1883, 10.1016/j.juro.2007.07.030

Motzer, 2004, Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma, J Clin Oncol, 22, 454, 10.1200/JCO.2004.06.132

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Figlin, 2008, Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC), J Clin Oncol, 26, 256s

Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.20.1.289

Motzer, 2007, Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors, Eur J Cancer Suppl, 5, 301, 10.1016/S1359-6349(07)71140-0

Remák, 2007, Economic evaluations of sunitinib vs. interferon-alfa (IFN-a) in first-line metastatic renal cell carcinoma (mRCC), J Clin Oncol, 25

Gore, 2007, Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis, Eur J Cancer Suppl, 5, 299, 10.1016/S1359-6349(07)71134-5

Patard, 2008, Tyrosine kinase inhibitors in clinical practice: patient selection, Eur Urol Suppl, 7, 601, 10.1016/j.eursup.2008.06.001

Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7

Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Abstract presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14–16, 2008; San Francisco, CA, USA. Abstract 350.

Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838

Szczylik, 2007, Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results, J Clin Oncol, 25

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655

Bukowski, 2007, Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis, J Clin Oncol, 25, 240s

Escudier, 2007, A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC): final results, Eur J Cancer Suppl, 5, 299, 10.1016/S1359-6349(07)71135-7

US National Institutes of Health. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery [trial identifier NCT00326898]. http://www.clinicaltrials.gov.

Motzer RJ, Figlin R, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Oral presentation at: the Annual Meeting of American Society of Clinical Oncology; June 1–5, 2007; Chicago, IL, USA. Abstract 5024.